How a GLP-1 Telehealth Visit Actually Works, Start to Finish

Most GLP-1 telehealth sites are built to feel like e-commerce. You answer a quiz, swipe a credit card, and a box arrives. The friction has been sanded off on purpose. That's great for conversion, but it hides a surprising amount of medicine, law, and logistics.

We walked the entire pipeline — the same one you walk every month when your autoship renews — and broke it into its actual moving parts. If any one of these parts is missing or sketchy at the platform you're using, that's where the legitimacy problems start.

Step 1: The intake quiz (minutes 0–3)

The first screen is not a medical history. It's a marketing funnel. Height, weight, goal, maybe a couple of contraindication checkboxes. The form's purpose at this stage is to keep you clicking long enough to reach the payment page before you bounce.

A legitimate platform asks the clinical questions after payment — because it legally cannot prescribe based on the quiz alone. The quiz is the ad; the medical record is built later.

Step 2: Payment and the real intake form (minutes 3–10)

After the credit card clears, the actual medical history opens. Comorbidities, current medications, thyroid cancer family history, pancreatitis, gallbladder issues, pregnancy status. This is the form that will be reviewed by a clinician. It is also the form whose accuracy is legally on you.

Most platforms ask for a government ID at this step. A few ask for lab work. A few more will accept "self-reported weight" with no verification — that's a flag worth noticing.

Step 3: The clinician review (hours 2–48)

This is where the visible part of the process ends and the invisible part begins. Your intake form lands in a queue. A nurse practitioner — almost never a physician — reviews it, often asynchronously, often in batches of dozens at a time.

Under the U.S. tele-prescribing framework loosened during COVID and extended via the DEA's telemedicine flexibilities, most non-controlled prescriptions can be written after an async review alone. Semaglutide and tirzepatide are not controlled substances. So the NP is legally allowed to write the prescription without ever speaking to you.

Whether they should is a different question. We get to that in Article #2.

Step 4: The prescription routing (hours 24–72)

Once approved, the prescription is routed — usually electronically — to one of two kinds of pharmacy:

• A 503A compounding pharmacy. Traditional pharmacy that mixes drugs per-patient. Compounds tirzepatide or semaglutide from raw API. Regulated by state pharmacy boards.
• A 503B outsourcing facility. FDA-registered, compounds in bulk without patient-specific prescriptions, must follow Current Good Manufacturing Practice (cGMP). Higher bar, tighter oversight.

Brand-name platforms (Sesame Care, LillyDirect) route to standard retail or mail-order pharmacies that fill pre-made Wegovy or Zepbound pens — no compounding at all.

Step 5: Compounding and quality control (days 2–5)

If your prescription is compounded, the pharmacy begins a mixing workflow: weigh API, dissolve in bacteriostatic water, pass through a sterile filter, fill vials, cap, label, quarantine, release. A reputable 503A does at least per-batch sterility and potency testing via a third-party lab.

What is actually in your vial at this stage depends entirely on the pharmacy. Several state pharmacy board actions in 2024 and 2025 found compounded GLP-1 products at under-dose, over-dose, or contamination levels the labels did not disclose. This is not hypothetical; it's documented.

Step 6: Shipping (days 3–8)

Compounded GLP-1s ship cold — usually with gel packs, occasionally with dry ice, almost always overnight or 2-day. The package's return address is the pharmacy, not the telehealth company. If you ever want to know who actually filled your prescription, look at the shipping label, not the website.

Shipping is where two other edge cases live: state-line restrictions (some states don't allow out-of-state 503A shipments), and the "no prescription label" problem we cover separately in Article #14.

Step 7: The ongoing subscription (month 2 onward)

After the first ship, most platforms move you to autoship. This is where the business model quietly shifts. The first month was about acquiring you. Every month after is high-margin renewal with near-zero incremental customer-acquisition cost.

Some platforms require a quarterly "check-in" — a second async questionnaire. Others just keep shipping. The one-year retention rate across the industry appears to be below 50% (CDC and commercial-claims data both suggest that range), which means the business is highly sensitive to your first 90 days.

Where the $199 actually goes

A rough breakdown of a typical all-in monthly charge on a compounded tirzepatide plan at the industry median price:

• ~$40–70: The compounded medication itself (API cost is genuinely low; most of the "drug cost" is pharmacy overhead and sterility testing).
• ~$25–40: Clinician review fee, split between the NP and the platform.
• ~$15–25: Cold shipping.
• ~$20–40: Platform overhead — software, payment processing, support, insurance.
• ~$50–80: Margin + customer acquisition recovery (your $199 in month two is paying off the ad that convinced you to sign up in month one).

The numbers shift by platform. Budget providers run thinner margins on month one and fatter margins on autoship. Premium platforms charge more but often provide more clinician time. Brand-name platforms pay a real drug cost ($500+ wholesale for Wegovy or Zepbound) and make almost nothing on the medication itself.

What a good telehealth visit does that a bad one skips

After running this pipeline across dozens of platforms, a short list of things the legitimate ones do and the sketchy ones skip:

1. They require ID verification and don't let pseudonyms through.
2. They require at least one real data point — recent lab, current weight on video, existing medication list — before prescribing.
3. They disclose the compounding pharmacy by name. You should be able to Google it and find a NABP record.
4. They disclose the prescribing clinician by name and NPI. You should be able to look the NPI up on the CMS NPI Registry and find a real license.
5. They have a documented titration protocol, not just "increase every 4 weeks."
6. They provide a mechanism to reach a clinician for side effects — not just a chatbot.
7. They don't resist cancellation, and they don't lock renewals behind a second intake.

If your current platform hits fewer than four of those seven, you're not on a healthcare service. You're on a subscription product that happens to ship a drug.

The takeaway

Telehealth for GLP-1 isn't illegitimate by default — it's a real medical model with real clinicians, real pharmacies, and real regulatory oversight. But "real" varies wildly. The same click path can lead you to a platform with board-certified obesity medicine physicians and 503B-sourced medication, or to one where a single NP rubber-stamps 400 prescriptions a day from a P.O. box. The visible parts look identical. The invisible parts are everything.

The rest of this site is essentially a field guide to the invisible parts. Start with the red flag checklist if you want to audit your current provider in ten minutes.